European Psychiatry - Volume 33 - March 2016

319 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S315
Objectives Olfactory identification deficits are well described in
schizophrenia while the results for pleasantness ratings remain
unclear.
Aims Evaluation of odor identification and hedonic judgment
related to severity of negative symptoms and -endorphin con-
centration.
Methods Fifty outpatients with schizophrenia were included in
the study: 25 with negative symptoms (PN) and 25 without pre-
dominant negative symptoms (P). They were compared with 23
healthy individuals. In all study groups University of Pennsylva-
nia Smell Identification Test (UPSIT) and odor hedonic evaluation
were performed. Clinical symptoms severity was evaluated using
PANSS. Plasma concentrations of -endorphin were assayed in all
participants.
Results PN made more odor identification errors than controls
(P = 0.000) and P sample (P= 0.001). Hedonic judgments of unpleas-
ant odors were significantly more pleasant in PN sample than in P
(P = 0.03) and controls (P = 0.041). PN had significantly higher con-
centration of -endorphin than P sample (P = 0.014) and controls
(P = 0.009). No relationship between -endorphin concentration
and odors identification and odor hedonic judgment was found in
both patient samples and controls.
Conclusions Increased level of -endorphin is related to pre-
dominance of negative symptoms but probably it is not involved
in olfactory identification performance and hedonic judgment
in schizophrenia. Patients with predominant negative symptoms
revealed different pattern of pleasantness rating – they experience
unpleasant odors as more pleasant. Alterations in smell identifi-
cation and hedonic judgment could be differentially expressed in
some subtypes of schizophrenia.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW567
Assessment of suicide risk in
schizophrenia with addictive
comorbidity
D. Vasile ∗, O. Vasiliu , D.G. Vasiliu , F. Vasile
Central University and Emergency Military Hospital “Dr. Carol
Davila”, Psychiatry, Bucharest, Romania
∗ Corresponding author.
Introduction Comorbid drug use disorders are associated with
greater risk for relapse in schizophrenia and lower adherence
to treatment. A comprehensive evaluation of patients with dual
diagnosis should address the problem of suicide risk, which is a
reputated complication of both psychotic disorders and drug use
disorders.
Objectives Depression and suicide risk assessment in subjects
diagnosed with schizophrenia and drug related disorders.
Aims To establish a protocol for early intervention in cases with
depressive features that associate suicide risk.
Methods All the patients (n = 37, female n = 15, male n = 12) with
both schizophrenia and a drug related disorder, consecutively
admitted in our department during a 6-month period, were eval-
uated using Calgary Depression Scale for Schizophrenia (CDSS),
Positive and Negative Syndrome Scale (PANSS), Inventory of Drug
Taking Situations (IDTS), Clinical Global Impression- Severity (CGI-
S). Subjects were evaluated at admission, discharge and after 3
months.
Results A percentage of 21.6 of all patients registered CDSS score
at baseline above the cutt-off score for a major depressive episode
of 6, while 10.8% had CDSS score of 6 and 8.1% had a CDSS score of 5.
IDTS had greater scores in all these 15 patients with high CDSS val-
ues, comparative to the other, <4 CDSS score patients. Psychological
counseling and treatment adjustmentsweremade accordingly, and
after 3 months CDSS scores declined in all the subjects (P < 0.01).
Conclusions Using a specific method for depression and suicide
risk in patients with schizophrenia and drug related disorder is very
useful for establishing a specific treatment approach and monitor-
ing plan.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW568
Insight, self-stigma and depressive
symptoms among patients with
schizophrenia
D. Vidovic ∗, P. Brecic , I. Jolic , V. Jukic
1 Univeristy Psychiatric Hospital Vrapce, Department for
Psychophysiology, Zagreb, Croatia
2 University Psychiatric Hospital Vrapce, Department for Treatment
and Rehabilitation, Zagreb, Croatia
3 University Psychiatric Hospital Vrapce, Department for Forensic
Psychiatry, Zagreb, Croatia
∗ Corresponding author.
Depressive symptoms are rather prevalent among patients with
schizophrenia and various factors can influence them. Insight and
self-stigma shows complex and contradictory relationship, both
are among most important features of schizophrenia with strong
impact on depressive symptoms. We wanted to test hypothesis
that preserved insight is related to depressive symptoms only
when self-stigma is also high. Our cross-sectional research com-
prised 149 patients with diagnosis of schizophrenia, both gender,
age span 25-45 years. Rating scales used were Calgary Depres-
sion Scale (CDS), Scale to assess Unawareness of Mental Disorder
(SUMD) and Internalized Stigma in Mental Illness (ISMI) which
are specifically designed for patients with schizophrenia. Major-
ity of patients were male (72%), single or separated (85%). Relation
between selfstigma and depressive symptoms was statistically
significant (b = 0.12, 95% CI = [0.06, 0.19], = 0.32, t(135) = 3.89,
P < 0.001) such as relationbetween selfstigma and insight (b = –0.01,
95% CI = [–0.02,–0.001], = –0.17, t(135) = –2.20, P = 0.029). Post-
hoc analysis showed that among patients with extremely high
selfstigma (more than 90 centile), higher insight was related
to more depressive symptoms (b = –0.22, 95% CI = [–0.42,–0.02],
= –0.34, t = –2.23, P = 0.028). These results are important for tail-
oring specific antistigma programs for patients with high level of
insight in order to prevent deleterious impact of depressive symp-
toms on course of schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW569
Neurophysiological correlates of
negative symptom domains in
patients with schizophrenia
A. Vignapiano ∗, V. Montefusco , G.M. Plescia , G. Di Lorenzo ,
C. Niol Altamura Marasco . Giordano
A. Mucci alderisi
1 University of Naples SUN, Psychiatry, Naples, Italy
2 University of Rome “Tor Vergata”, Department of Systems Medicine,
Rome, Italy
3 University of Foggia, Department of Clinical and Experimental
Medicine- Psychiatry Unit, Foggia, Italy
∗ Corresponding author.
Introduction Negative symptoms have long been recognized as
a central feature of schizophrenia, which limit recovery, having a
strong negative impact on real-life functioning. External validators